Baird Financial Group Inc. Has $478,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Baird Financial Group Inc. reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 67.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,592 shares of the medical research company's stock after selling 5,494 shares during the quarter. Baird Financial Group Inc.'s holdings in Charles River Laboratories International were worth $478,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Pinnacle Bancorp Inc. increased its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after buying an additional 65 shares during the period. Optiver Holding B.V. purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth about $37,000. GeoWealth Management LLC grew its position in shares of Charles River Laboratories International by 311.5% in the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after purchasing an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International during the fourth quarter worth $48,000. Finally, Tortoise Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after acquiring an additional 115 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Analyst Ratings Changes

A number of analysts recently commented on CRL shares. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. William Blair lowered Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Robert W. Baird raised their price target on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $172.31.

Insider Buying and Selling

In other news, CEO James C. Foster purchased 6,075 shares of the stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Birgit Girshick bought 1,514 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 5,040 shares of company stock valued at $807,407. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Up 0.3%

Charles River Laboratories International stock traded up $0.39 during midday trading on Monday, hitting $141.36. 752,502 shares of the company were exchanged, compared to its average volume of 981,971. The company's fifty day moving average price is $135.43 and its 200-day moving average price is $164.76. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The company has a market cap of $6.94 billion, a PE ratio of 942.40, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the company posted $2.27 EPS. The business's revenue was down 2.7% compared to the same quarter last year. On average, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).